Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fridkin

Showing results (201-210 of 254) with videos related to

Pageof 26
Sort By:
Brain Research|January 20, 1992
Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonistJ R Glowa, L V Panlilio, D E Brenneman, et al.
Journal of Medicinal Chemistry|April 30, 1993
Structure-function studies of amphiphilic antibacterial peptidesR Bessalle, A Gorea, I Shalit, et al.
Neuroscience|August 28, 1999
Pharmacologically distinct vasoactive intestinal peptide binding sites: CNS localization and role in embryonic growthJ M Hill, S J Lee, D A Dibbern, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 15, 1993
A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growthT W Moody, F Zia, M Draoui, et al.
The Journal of Biological Chemistry|May 12, 1995
Archaebacterial and eukaryotic proteasomes prefer different sites in cleaving gonadotropin-releasing hormoneD Leibovitz, Y Koch, M Fridkin, et al.
Journal of Molecular Neuroscience : MN|January 1, 1994
Inhibition of human neuroblastoma growth by a specific VIP antagonistG Lilling, Y Wollman, M N Goldstein, et al.
Cancer|October 12, 2001
A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell linesE Gelber, R Granoth, M Fridkin, et al.
The Journal of Clinical Investigation|July 15, 1997
Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brainP Gressens, S Marret, J M Hill, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 9, 1996
Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptideI Gozes, A Bardea, A Reshef, et al.
The Journal of Laboratory and Clinical Medicine|November 21, 1998
Effect of serum amyloid A on selected in vitro functions of isolated human neutrophilsM E Gatt, S Urieli-Shoval, L Preciado-Patt, et al.
Pageof 26

Showing results (201-210 of 254) with videos related to

Sort By:
Pageof 26
Brain Research|January 20, 1992
Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonistJ R Glowa, L V Panlilio, D E Brenneman, et al.
Journal of Medicinal Chemistry|April 30, 1993
Structure-function studies of amphiphilic antibacterial peptidesR Bessalle, A Gorea, I Shalit, et al.
Neuroscience|August 28, 1999
Pharmacologically distinct vasoactive intestinal peptide binding sites: CNS localization and role in embryonic growthJ M Hill, S J Lee, D A Dibbern, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 15, 1993
A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growthT W Moody, F Zia, M Draoui, et al.
The Journal of Biological Chemistry|May 12, 1995
Archaebacterial and eukaryotic proteasomes prefer different sites in cleaving gonadotropin-releasing hormoneD Leibovitz, Y Koch, M Fridkin, et al.
Journal of Molecular Neuroscience : MN|January 1, 1994
Inhibition of human neuroblastoma growth by a specific VIP antagonistG Lilling, Y Wollman, M N Goldstein, et al.
Cancer|October 12, 2001
A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell linesE Gelber, R Granoth, M Fridkin, et al.
The Journal of Clinical Investigation|July 15, 1997
Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brainP Gressens, S Marret, J M Hill, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 9, 1996
Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptideI Gozes, A Bardea, A Reshef, et al.
The Journal of Laboratory and Clinical Medicine|November 21, 1998
Effect of serum amyloid A on selected in vitro functions of isolated human neutrophilsM E Gatt, S Urieli-Shoval, L Preciado-Patt, et al.
Pageof 26